TRANSDERMALES PFLASTER MIT RIVASTIGMIN

European patent · EP3501518 · In force

Register entry

Publication number
EP3501518
Application number
EP17843502
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Aug 21, 2017
Published
Jun 26, 2019
Granted
May 14, 2025
Protection ends at the latest
Aug 20, 2037
Next annual fee due
Aug 31, 2027
IPC classes
A61K 9/70 (2006.01)
A61K 47/12 (2006.01)
A61K 31/27 (2006.01)
A61K 31/202 (2006.01)
A61P 25/28 (2006.01)
Priority
JP 2016161730 22.08.2016
PCT application
PCT/JP2017/029697 21.08.2017
PCT publication
WO2018/038022 01.03.2018
Filing language
Japanese
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.08.2026 → 31.08.2027

    Published in Swissreg on 01.09.2026

  2. Mar 25, 2026

    Change

    Published in Swissreg on 25.03.2026

  3. Sep 1, 2025

    Next annual fee due on

    Next annual fee due on
    31.08.2025 → 31.08.2026

    Published in Swissreg on 01.09.2025

  4. May 23, 2025

    Agent entered

    Representative
    BOVARD AG, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 23.05.2025

  5. May 14, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 14.05.2025

Parties

Holder

KYUKYU PHARMACEUTICAL CO., LTD.

Kyukyu Pharmaceutical Co., Ltd.

2-10, Nihonbashi Honcho 4-chome Chuo-ku, Tokyo 103-0023, JP

Agent

Bovard AG

BOVARD AG

Optingenstrasse 16, 3013 Bern

Inventor

FUTATSUYA, Akihiro

Imizu-shi Toyama 939-0351, JP

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.